An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease
ConclusionCT-P13 is effective and well tolerated in short and long-term periods. Switching to CT-P13 is recommended for the management of IBD.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
More News: Clinical Trials | Crohn's Disease | Gastroenterology | Inflammatory Bowel Disease | Remicade | Science | Study | Ulcerative Colitis